Join
Live feed
·
PRReleasevia Quantisnow
Nuvation Bio Inc. logo

Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer

ByQuantisnow·Wall Street's wire, on your screen.
NUVB· Nuvation Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NUVB (Nuvation Bio Inc.) and more on Quantisnow.